Kolexia
Linassier Claude Oncologie médicale
Linassier Claude
Oncologie médicale
Centre hospitalier de Tours
Tours, France
117 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinomes Néphrocarcinome Métastase tumorale Tumeurs de la prostate Tumeurs du rein Sarcomes Récidive tumorale locale Tumeurs embryonnaires et germinales Adénocarcinome

Collaborateurs

Voir plus
Gravis-Mescam Gwenaelle
Gravis-Mescam Gwenaelle
Centre Paoli-Calmettes, Marseille, France
Rolland Frederic
Rolland Frederic
Institut de cancérologie de l'Ouest, Saint-Herblain, France
Oudard Stephane
Oudard Stephane
Hôpital Européen Georges Pompidou, Paris, France
Theodore Christine
Theodore Christine
Hôpital Foch, Suresnes, France

Industries

Voir plus
A+A
38 collaboration(s)
Dernière en 2023
AstraZeneca
16 collaboration(s)
Dernière en 2023
Bayer
15 collaboration(s)
Dernière en 2023
Ipsen
9 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors: A Risk-Adapted Strategy of the Use of Dose-Dense Chemotherapy in Patients With Poor-Prognosis Disseminated Non-Seminomatous Germ Cell Tumors
Essai Clinique (Unicancer)   01 février 2024
Gastrointestinal metastases in renal cell carcinoma: A retrospective multicenter GETUG (Groupe d'Étude des Tumeurs Uro-Génitales) study.
European journal of cancer (Oxford, England : 1990)   15 janvier 2024
La Consult' de Claude Linassier : "On veut vacciner 80 % de la population contre le HPV avant 2030"
Youtube @ What's up Doc   01 octobre 2023
Impact of First Line Antiangiogenic Therapy Duration on Nivolumab Outcome in Metastatic Renal Cell Carcinoma Patients Treated in the GETUG-AFU 26 NIVOREN.
Clinical genitourinary cancer   20 juillet 2023
ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable): A Double-blind Randomised Phase III Trial Evaluating the Efficacy of ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability and Not Elected for Docetaxel or Androgen Receptor Targeted Agents
Essai Clinique (Bayer)   10 mai 2023
Very Long-Term Complete Remission Can Be Achieved in Men With High-Risk Localized Prostate Cancer and a Very High PSA Value: An Analysis of the GETUG 12 Phase 3 Trial.
Clinical genitourinary cancer   07 mai 2023
SPICI: Strategic Treatment Pause of First-line Immune Check Point Inhibitor + VEGFR-Tyrosine Kinase Inhibitor in Good or Only One Adverse Prognostic Factor in Intermediate Risk Metastatic Renal Cell Carcinoma (mRCC) With an Objective Response: a Randomised, Non-inferiority Phase III Study
Essai Clinique (CHU Bordeaux)   10 mars 2023
Abigene, a Prospective, Multicentric Study of Abiraterone Acetate Pharmacogenetics in Metastatic Castration-Resistant Prostate Cancer.
Pharmaceutics   15 février 2023
Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse: Phase III Randomized Study Of Adjuvant Hormonal Therapy With And Without Docetaxel And Estramustine In Patients With Advanced Prostate Cancer Or With A High Risk Of Relapse
Essai Clinique (Sanofi)   17 janvier 2023
Frontline immune checkpoint inhibitor-based combination therapy in metastatic renal cell carcinoma patients with poor performance status.
European journal of cancer (Oxford, England : 1990)   26 novembre 2022